Summit Therapeutics Inc.
No SEC Form 4 filings for $SMMT in the last 30 days.
See all $SMMT insider activity →Jefferies upgraded Summit Therapeutics (SMMT) to 'Buy' with a $25.00 price target, up from $15.00. The company has a $13.99B market cap, a GF Score of 30, and significant insider buying. SMMT focuses on novel antibiotics, with ridinilazole targeting Clostridiodes difficile infections. The high P/S ratio suggests overvaluation.
Summit Therapeutics (SMMT) shares rose 5.8% premarket after Jefferies upgraded it to Buy and raised its price target to $25. The upgrade is ahead of expected H3 progression-free survival data in late 2026, with Jefferies predicting statistical significance and a potential overall survival win by early 2027. The analyst cited the company's mechanism of action and ivonescimab's first-in-class status as key drivers.
Summit Therapeutics (SMMT) announced that its partner Akeso reported a statistically significant overall survival benefit for ivonescimab over pembrolizumab in the Phase 3 HARMONi-2 study. The trial involved 398 patients with advanced non-small cell lung cancer. Earlier data showed ivonescimab's median progression-free survival was 11.1 months, compared to 5.8 months for pembrolizumab. The hazard ratio was 0.51, indicating a 49% reduction in progression or death risk. Summit did not disclose the
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning SMMT (Summit Therapeutics Inc.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent SMMT coverage spans technology, financial news and market movers.
Analyst upgrade and higher price target suggest near‑term upside potential.
Upgrade suggests near‑term upside as analysts expect positive trial outcomes.
The OS benefit suggests a potentially practice‑changing advantage for ivonescimab, likely boosting Summit's valuation.
Positive topline data suggests strong efficacy, likely boosting near‑term demand for the stock.
Positive trial data drives biotech rally.
AlphAI scores every news story that mentions SMMT with an AI model for sentiment and relevance, and aggregates insider trades from Summit Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jefferies upgraded Summit Therapeutics (SMMT) to 'Buy' with a $25.00 price target, up from $15.00. The company has a $13.99B market cap, a GF Score of 30, and significant insider buying. SMMT focuses on novel antibiotics, with ridinilazole targeting Clostridiodes difficile infections. The high P/S ratio suggests overvaluation.
2 min readSummit Therapeutics (SMMT) shares rose 5.8% premarket after Jefferies upgraded it to Buy and raised its price target to $25. The upgrade is ahead of expected H3 progression-free survival data in late 2026, with Jefferies predicting statistical significance and a potential overall survival win by early 2027. The analyst cited the company's mechanism of action and ivonescimab's first-in-class status as key drivers.
1 min readSummit Therapeutics (SMMT) announced that its partner Akeso reported a statistically significant overall survival benefit for ivonescimab over pembrolizumab in the Phase 3 HARMONi-2 study. The trial involved 398 patients with advanced non-small cell lung cancer. Earlier data showed ivonescimab's median progression-free survival was 11.1 months, compared to 5.8 months for pembrolizumab. The hazard ratio was 0.51, indicating a 49% reduction in progression or death risk. Summit did not disclose the
2 min readSummit Therapeutics (SMMT) shares rose 28.19% week-on-week after its partner, Akeso, reported positive Phase 3 trial results for ivonescimab in non-small cell lung cancer, showing improved overall survival over pembrolizumab. Additionally, ivonescimab demonstrated superiority in a biliary tract cancer trial. Final results are pending presentation at medical conferences. Institutional investors reduced holdings despite increased hedge fund interest.
2 min readU.S. stocks rallied after Fed Governor Christopher Waller suggested a potential September rate hold. Bitcoin surged 4.6% to $80,900. Tesla, Meta, and Microsoft led gains, while Broadcom and Tyson Foods declined. Snowflake rose 21.9% on strong earnings and raised guidance. The S&P 500 and Nasdaq 100 each gained over 0.9%.
3 min readSummit Therapeutics' (SMMT) experimental cancer drug, ivonescimab, showed better overall survival rates in a study compared to Merck's (MRK) Keytruda. This led to a stock surge for Summit and a four-month high for Crescent Biopharma (CBIO).
2 min readSummit Therapeutics (SMMT) shares rose 10.1% to $16.07 after positive Phase III study results. Snowflake (SNOW) gained 20.6% following better-than-expected earnings. HUTCHMED (HCM) rose 13% after a licensing deal. Tesla (TSLA) increased 5.7% to $377.53. Other stocks like Robinhood (HOOD), Coinbase (COIN), and others also saw gains.
2 min readAkeso Inc. reported positive overall survival results from the HARMONi-2 study, showing ivonescimab monotherapy outperformed pembrolizumab in PD-L1-positive advanced NSCLC. Summit Therapeutics (SMMT) noted the findings, with ivonescimab approved in China and under investigation in other regions. The study's hazard ratio was 0.51 (p<0.0001). Summit is conducting further trials, including HARMONi-7 for PD-L1 high-expressing NSCLC.
2 min readSummit Therapeutics (SMMT) shares rose 3% after its partner Akeso reported positive Phase III trial results for ivonescimab, showing a survival advantage over pembrolizumab in lung cancer. The company has a high P/S ratio of 369.4x, reflecting growth expectations. Insiders bought $126.6M in shares, but the company remains unprofitable.
2 min readCantor Fitzgerald reiterated an Overweight rating on Summit Therapeutics (SMMT), citing undervaluation despite a 42.5% stock decline. The firm compared SMMT to Moderna, highlighting clinical data for ivonescimab. Analysts' price targets range from $10.96 to $41.73. Recent Phase III trial results showed ivonescimab's potential, with mixed analyst reactions.
1 min read
